OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
23 avr. 2024 16h15 HE
|
OpGen, Inc.
ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”)...
OpGen Announces Acquisition of Preferred Stock by David Lazar
25 mars 2024 16h05 HE
|
OpGen, Inc.
David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March ...
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
14 nov. 2023 16h30 HE
|
OpGen, Inc.
Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives,...
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
12 oct. 2023 12h32 HE
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
10 août 2023 16h15 HE
|
OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
07 août 2023 07h30 HE
|
OpGen, Inc.
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now availableAdded reporting customized for the needs of hospital epidemiologists Signed first large commercial...
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
03 août 2023 08h00 HE
|
OpGen, Inc.
Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICsNext phase to cover full AMR assay and cartridge...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
03 août 2023 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
19 juil. 2023 07h30 HE
|
OpGen, Inc.
All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
26 juin 2023 07h30 HE
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...